The Veterinary clinics of North America. Equine practice2024; S0749-0739(24)00030-0; doi: 10.1016/j.cveq.2024.04.004

Approach to Inflammatory Bowel Disease.

Abstract: Inflammatory bowel disease (IBD) in the horse encompasses a group of infiltrative gastrointestinal disorders resulting in malabsorption, maldigestion, weight loss, colic, and sometimes diarrhea. The type of IBD can be classified as granulomatous, lymphocytic-plasmacytic, or eosinophilic enterocolitis. The diagnosis of IBD in equids is based on consistent clinical signs and clinicopathologic findings in conjunction with confirmatory histopathology from a gastrointestinal biopsy. Treatment usually consists of a combination of immunosuppressive medications, anthelmintics, and dietary modifications. The prognosis of IBD in horses is variable and dependent on the horse's response to treatment; however, horses can show improvement or resolution of clinical signs.
Publication Date: 2024-05-23 PubMed ID: 38789349DOI: 10.1016/j.cveq.2024.04.004Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research investigates inflammatory bowel disease (IBD) in horses, which is a group of gastrointestinal disorders. It discusses IBD types, diagnosis methods, treatment approaches, and prognosis for horses with IBD.

Overview of Inflammatory Bowel Disease in Horses

  • Inflammatory bowel disease (IBD) in horses is a complex group of gastrointestinal diseases that results in malabsorption, maldigestion, weight loss, colic, and sometimes diarrhea.
  • IBD can be classified into granulomatous, lymphocytic-plasmacytic, or eosinophilic enterocolitis depending on the predominant immune cell type infiltrating the gut wall.

Diagnosting IBD in Equids

  • IBD diagnosis in horses relies on consistent clinical signs and clinicopathologic findings in combination with confirmatory histopathology from a gastrointestinal biopsy. This means that a tissue sample is taken from a horse’s digestive system, and it is examined under a microscope to accurately identify the presence and type of IBD.
  • It’s not only about identifying the disease but also understanding its severity and potential impact on the horse’s overall health, which supports in designing the most effective treatment plan.

Treatment Approaches

  • Typically, treating IBD in horses includes a combination of immunosuppressive medications, anthelmintics, and modifications in the horse’s diet.
  • Immunosuppressive medications help control the body’s immune response, which can reduce inflammation in the bowel.
  • Anthelmintics are a class of drugs used to expel or destroy parasitic worms and are included in the event that parasitic infection may have contributed to the development or exacerbation of the disease.
  • Dietary modifications aim to adjust the horse’s food intake to something that can be more easily digested given the altered state of the horse’s gut.

Prognosis of Equine IBD

  • IBD prognosis in horses is highly variable and largely depends on the horse’s response to treatment. Not every horse responds to treatment in the same way; hence, the outcomes can differ from horse to horse.
  • Despite the variability, it is possible for horses to show improvement or even complete resolution of clinical signs over time with the correct intervention.

Cite This Article

APA
Timko K. (2024). Approach to Inflammatory Bowel Disease. Vet Clin North Am Equine Pract, S0749-0739(24)00030-0. https://doi.org/10.1016/j.cveq.2024.04.004

Publication

ISSN: 1558-4224
NlmUniqueID: 8511904
Country: United States
Language: English
PII: S0749-0739(24)00030-0

Researcher Affiliations

Timko, Kathryn
  • College of Veterinary Medicine, The Ohio State University, 601 Vernon L Tharp Street, Columbus, OH 43201, USA. Electronic address: Timko.38@osu.edu.

Conflict of Interest Statement

Disclosure The author has nothing to disclose.

Citations

This article has been cited 0 times.